

SINOVAC



Supply Vaccines to Eliminate Human Diseases

Corporate Introduction

科兴控股生物技术有限公司
SINOVA C BIOTECH LTD.

The logo for SINO VAC, with 'SINO' in black and 'VAC' in red, all in a bold, sans-serif font.

SINO VAC


Supply Vaccines to Eliminate Human Diseases

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases.

科兴控股生物技术有限公司
SINO VAC BIOTECH LTD.

Group Structure

SINOVAC



Our History & Products

SINOVAC

We focus on the Research, Development, Manufacture and Commercialization of vaccines for infectious diseases with significant unmet medical need.

2001

SINOVAC

Sinovac Beijing
Established

2004

Inactivated SARS Vaccine
(Phase 1 Completed)

2006



Influenza Vaccine (Split Virion), Inactivated

2009



H1N1 Influenza A Vaccine (Split Virion), Inactivated

SINOVAC

Sinovac LifeSciences
Established

2012



Mumps vaccine, Live

2020...



Varicella Vaccine, Live
Quadrivalent Influenza Vaccine
COVID-19 Vaccine
PPV23
Sabin-IPV

Provide Chinese Children with Top Quality Vaccines, Provide Children around the World with Vaccines Made in China

Hepatitis A Vaccine,
Inactivated
(WHO PQ, 2017)



2002

Hepatitis A & Hepatitis B
Combined Vaccine



2005

Pandemic Influenza
Vaccine, Inactivated
(H5N1)



2008

Sinovac Dalian Established
SINOVAC

2010

Enterovirus Type 71
Vaccine, Inactivated



2016

Domestic Market


SINOVAC



 Covered Provinces
 Uncovered Provinces

Coverage: 29 provinces & municipalities


Coverage rate: 86% (34 provinces & municipalities)



Worldwide Market & Footprint

SINOVAC

- The cumulative global sales are nearly 160 million doses. In 2019, an average of 112 people per minute were vaccinated with Sinovac's vaccines to obtain immune protection.
- Sinovac's vaccine has been sold in 22 countries around the world, has been registered in 17 countries, and is being registered in 26 countries, covering 3.25 billion people 68 million newborns
- The hepatitis A vaccine Healive® is the first HepA vaccine in China to pass WHO-PQ, and is being exported to more than 10 "Belt and Road" countries and international organizations such as PAHO.



Production Sites

SINOVAC

Area: 22264.21 m²
Floorage: 14200.38 m²

- HepA
- Influenza
- HepA&B combo
- PPV23

Haidian-Beijing (Headquarter)



Dalian-Liaoning



Area: 95685.6m²
Floorage: 20000m²

- Mumps
- Varicella

Area: 29021m²
Floorage: 32322m²

- EV71
- Sabin-IPV



Changping-Beijing



Daxing-Beijing

Area: 45523 m²
Floorage: 69124.5 m²

- Sars -Cov-2
-

- Beijing(Haidian, Changping, Daxing sites), and Dalian site. 4 sites in total
- Total area:192,000m²
- Total floorage:136,000m²

Quality Accreditation



China



Cuba



Nepal



Nigeria


MINISTÉRIO DA SAÚDE
AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA
CERTIFICADO DE BOAS PRÁTICAS DE FABRICAÇÃO DE MEDICAMENTOS
LINHA DE INSUMOS FARMACÊUTICOS ATIVOS BIOLÓGICOS

A Agência Nacional de Vigilância Sanitária - ANVISA, por meio da Resolução RDC nº 2.221, de 01/07/2020, publicada em Diário Oficial da União (DOU) na data de 05/07/2020, certifica que a empresa objeto é periodicamente inspecionada e monitorada pelo Sistema Nacional de Vigilância Sanitária e que cumpre com as diretrizes de Boas Práticas de Fabricação dadas pela legislação brasileira, a qual está em consonância com as recomendações da Organização Mundial de Saúde.

Fabricante: Sinovac Biotech Co. LTD.
 Endereço: Nº 39, Shuangli Xi Road, Hubei District, 100068, Beijing (Pequim)
 País: República Popular da China Gênero Único: A 1404
 Solicitante: Bio Medicamentos Ltda CNPJ: 15.209.488/0001-40
 Autorização de Funcionamento: 1.14.566-7 Expediente(s): 0115791/20-6
 Certificado de Boas Práticas de Fabricação de Medicamentos:
 Insumos farmacêuticos ativos biológicos: vacina subvirulenta hepatite A (inativada).

A presente certificação é válida até o dia 05/07/2022 e poderá ser cancelada, caso seja comprovado, pela autoridade sanitária competente, o não cumprimento dos requisitos preconizados pelas normas vigentes de Boas Práticas.

Documento assinado eletronicamente por **Ronaldo Lucio Ponciano Gomes, Gerente-Geral de Inspeção e Fiscalização Sanitária**, em 05/07/2020, às 09:36, conforme protocolo oficial de Brasília, com fundamento no art. 6º, § 1º, do Decreto nº 8.539, de 8 de outubro de 2015 http://www.planalto.gov.br/ccivil_03/_ato2015/2015/010/201500922.htm

A autenticação deste documento pode ser conferida no site brasil.gov.br informando o código verificador **1072008** e o código CRC AFD1C3E.



Brazil

Reference: 311.1 20/12/2017


World Health Organization
HEALIVE

Hepatitis A (Human Diploid Cell, Inactivated (Adult))

Product Overview:

Type:	Hepatitis A (Human Diploid Cell, Inactivated (Adult))	
Commercial Name:	HEALIVE	
Manufacturer:	Sinovac Biotech Co. Ltd	
Country:	People's Republic of China	
URL:		
Responsible NRA:	State Food and Drug Administration	
Country:	People's Republic of China	
URL:		
Bulk Supplier:	Not applicable	

Prequalification:

Prequalification Status: Current
 Effective Date (ddmm/yyyy):

Product Description:

Pharmaceutical Form:	Liquid, ready to use
Presentation:	Vial
Number of Doses:	1
Diluent:	Not Applicable
Route of Administration:	Intramuscular
Shelf Life:	at storage temperature: -2-8°C
Vaccine Vial Monitor:	Type 30
Secondary Packaging:	Single dose carton [Dimensions 2.5 x 2.5 x 5.5 cm]
Tertiary Packaging:	Box of 40 wrapped packages with 10 single dose cartons (400 doses/400 vials [Dimensions: 47 x 36 x 38 cm])
Cold Chain Volume:	3.3 ^{ml/3-dose} (in secondary packaging)

المملكة الصحية العالمية • 世界卫生组织
 Organización Mundial de la Salud • Български оправа за здравеопазване • Organización Mundial de la Salud

WHO PQ


Total GMPs: 11 Certificates

Total MAs : 33 product Certificates





Leveraging Our Proven Track Record in Vaccine Development,
SINO-VAC's Future Growth is Driven by Advancement of Our Pipeline Product.



Total R&D: 9 projects

International Coordination

SINOVAC

dcvmmn

Developing Countries Vaccine
Manufacturers Network

&



IFPMA

International Federation
of Pharmaceutical
Manufacturers & Associations

(Member)

+

SINOVAC

Partnership

PAHO  Pan American
Health
Organization

 **World Health
Organization**
REGIONAL OFFICE FOR THE **Americas**


unicef  | for every child

PUBLICATIONS

SINOVAC

- More than 50 invention patents
- Published more than 120 SCI papers on vaccine research, total impact factor exceeded 300 points.

Science 

 The NEW ENGLAND
JOURNAL of MEDICINE

THE LANCET

 nature
International Journal of science



Working Together for a Healthier World

SINOVAC



SINOVAC

Supply Vaccines to Eliminate Human Diseases



sinovac.com



SINOVAC : Supply Vaccines to Eliminate Human Diseases



科兴控股生物技术有限公司
SINOVAC BIOTECH LTD.